What is CMI?
CMI, Inc. operates as a premier manufacturer of breath alcohol testing instruments, most notably recognized for its industry-standard Intoxilyzer brand. With a legacy spanning over three decades, the company provides a sophisticated suite of solutions including handheld breath testers, desktop analytical instruments, and comprehensive calibration services. Utilizing advanced infrared spectrometry, CMI delivers high-fidelity data essential for regulatory compliance and public safety. As a wholly-owned subsidiary of MPD, Inc., the firm maintains a strategic focus on delivering reliable, high-accuracy detection systems to military, educational, and law enforcement sectors worldwide.
How much funding has CMI raised?
CMI has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in CMI
PPP
Public-Private Partnership
What's next for CMI?
With the successful completion of this late-stage financing, CMI is well-positioned to accelerate its research and development initiatives, particularly in the refinement of infrared spectrometry applications. The strategic allocation of these funds will likely focus on expanding the company's global footprint and enhancing its service infrastructure to meet the evolving demands of international law enforcement agencies. As the regulatory landscape for alcohol detection becomes increasingly stringent, CMI's focus on technological reliability and product innovation will be pivotal in maintaining its competitive advantage and driving long-term growth in the safety instrumentation market.
See full CMI company page
